HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
The Week

EHA: J&J sharpens myeloma edge as Talvey, Darzalex Faspro combo proves its worth in earlier disease stage

J&J's MonumenTAL-3 phase 3 study of bispecific antibody Talvey and Darzalex Faspro in patients with earlier-stage multiple myeloma earned a plenary spot at the 2026 European Hematology Association annual meeting.

By FiercePharma · Jun 13, 2026 · via FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
'I wouldn't call it a blip': Biotech IPOs here to stay after another record-breaking listing
The WeekFierceBiotech ↗
'I wouldn't call it a blip': Biotech IPOs here to stay after another record-breaking listing
Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings …
Jun 13, 2026
Prometheus collects $12B for “artificial engineers”
The WeekBriefing
Prometheus collects $12B for “artificial engineers”
Prometheus secured $12 billion to build its “artificial engineers,” part of a week of biotech activity spannin…
Jun 13, 2026
The WeekAJMC ↗
Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD
Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD…
Jun 13, 2026